Design of biodegradable nanoparticles for oral delivery of Doxorubicin: in vivo pharmacokinetics and toxicity studies in rats

D.R. Kalaria, G. Sharma, V. Beniwal, M.N.V. Ravi Kumar

Research output: Contribution to journalArticle

188 Citations (Scopus)

Abstract

Doxorubicin, a potent anticancer drug associated with cardiotoxicity and low oral bioavailability, was loaded into nanoparticles with a view to improve its performance. Doxorubicin loaded PLGA nanoparticles were prepared by a double emulsion method. The pH dependent stability of nanoparticles in simulated fluids was evaluated. DSC and XRD studies were carried out in order to ascertain the nature of doxorubicin in formulations in conjunction with accelerated stability studies. The in vitro release was investigated in phosphate buffer. The pharmacokinetic and toxicity studies were conducted in rats. Nanoparticles had an average size of 185 nm, with 49% entrapment at 10% w/w of polymer. The particles displayed good pH dependent stability in the pH range 1.1-7.4. DSC and XRD studies revealed the amorphous nature of doxorubicin in nanoparticles and the accelerated stability studies revealed the integrity of formulations. Initial biphasic release (20%) followed by a sustained release (80%) for 24 days was observed under in vitro conditions. The doxorubicin loaded nanoparticles demonstrated superior performance in vivo as evident by enhanced bioavailability and lower toxicity. Together, the data indicates the potential of doxorubicin loaded nanoparticles for oral chemotherapy. Further, these formulations could be explored for new indications like leishmaniasis.
LanguageEnglish
Pages492-501
Number of pages9
JournalPharmaceutical Research
Volume26
Issue number3
DOIs
Publication statusPublished - 2008

Fingerprint

Pharmacokinetics
Nanoparticles
Doxorubicin
Toxicity
Rats
Biological Availability
Leishmaniasis
Chemotherapy
Emulsions
Buffers
Polymers
Phosphates
Drug Therapy
Fluids
Pharmaceutical Preparations

Keywords

  • bioavailability
  • cardiotoxicity
  • oral delivery
  • oxidative stress

Cite this

Kalaria, D.R. ; Sharma, G. ; Beniwal, V. ; Kumar, M.N.V. Ravi. / Design of biodegradable nanoparticles for oral delivery of Doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. In: Pharmaceutical Research. 2008 ; Vol. 26, No. 3. pp. 492-501.
@article{b27d442af62e44eca69f1a685e065d8a,
title = "Design of biodegradable nanoparticles for oral delivery of Doxorubicin: in vivo pharmacokinetics and toxicity studies in rats",
abstract = "Doxorubicin, a potent anticancer drug associated with cardiotoxicity and low oral bioavailability, was loaded into nanoparticles with a view to improve its performance. Doxorubicin loaded PLGA nanoparticles were prepared by a double emulsion method. The pH dependent stability of nanoparticles in simulated fluids was evaluated. DSC and XRD studies were carried out in order to ascertain the nature of doxorubicin in formulations in conjunction with accelerated stability studies. The in vitro release was investigated in phosphate buffer. The pharmacokinetic and toxicity studies were conducted in rats. Nanoparticles had an average size of 185 nm, with 49{\%} entrapment at 10{\%} w/w of polymer. The particles displayed good pH dependent stability in the pH range 1.1-7.4. DSC and XRD studies revealed the amorphous nature of doxorubicin in nanoparticles and the accelerated stability studies revealed the integrity of formulations. Initial biphasic release (20{\%}) followed by a sustained release (80{\%}) for 24 days was observed under in vitro conditions. The doxorubicin loaded nanoparticles demonstrated superior performance in vivo as evident by enhanced bioavailability and lower toxicity. Together, the data indicates the potential of doxorubicin loaded nanoparticles for oral chemotherapy. Further, these formulations could be explored for new indications like leishmaniasis.",
keywords = "bioavailability, cardiotoxicity, oral delivery, oxidative stress",
author = "D.R. Kalaria and G. Sharma and V. Beniwal and Kumar, {M.N.V. Ravi}",
year = "2008",
doi = "10.1007/s11095-008-9763-4",
language = "English",
volume = "26",
pages = "492--501",
journal = "Pharmaceutical Research",
issn = "0724-8741",
number = "3",

}

Design of biodegradable nanoparticles for oral delivery of Doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. / Kalaria, D.R.; Sharma, G.; Beniwal, V.; Kumar, M.N.V. Ravi.

In: Pharmaceutical Research, Vol. 26, No. 3, 2008, p. 492-501.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Design of biodegradable nanoparticles for oral delivery of Doxorubicin: in vivo pharmacokinetics and toxicity studies in rats

AU - Kalaria, D.R.

AU - Sharma, G.

AU - Beniwal, V.

AU - Kumar, M.N.V. Ravi

PY - 2008

Y1 - 2008

N2 - Doxorubicin, a potent anticancer drug associated with cardiotoxicity and low oral bioavailability, was loaded into nanoparticles with a view to improve its performance. Doxorubicin loaded PLGA nanoparticles were prepared by a double emulsion method. The pH dependent stability of nanoparticles in simulated fluids was evaluated. DSC and XRD studies were carried out in order to ascertain the nature of doxorubicin in formulations in conjunction with accelerated stability studies. The in vitro release was investigated in phosphate buffer. The pharmacokinetic and toxicity studies were conducted in rats. Nanoparticles had an average size of 185 nm, with 49% entrapment at 10% w/w of polymer. The particles displayed good pH dependent stability in the pH range 1.1-7.4. DSC and XRD studies revealed the amorphous nature of doxorubicin in nanoparticles and the accelerated stability studies revealed the integrity of formulations. Initial biphasic release (20%) followed by a sustained release (80%) for 24 days was observed under in vitro conditions. The doxorubicin loaded nanoparticles demonstrated superior performance in vivo as evident by enhanced bioavailability and lower toxicity. Together, the data indicates the potential of doxorubicin loaded nanoparticles for oral chemotherapy. Further, these formulations could be explored for new indications like leishmaniasis.

AB - Doxorubicin, a potent anticancer drug associated with cardiotoxicity and low oral bioavailability, was loaded into nanoparticles with a view to improve its performance. Doxorubicin loaded PLGA nanoparticles were prepared by a double emulsion method. The pH dependent stability of nanoparticles in simulated fluids was evaluated. DSC and XRD studies were carried out in order to ascertain the nature of doxorubicin in formulations in conjunction with accelerated stability studies. The in vitro release was investigated in phosphate buffer. The pharmacokinetic and toxicity studies were conducted in rats. Nanoparticles had an average size of 185 nm, with 49% entrapment at 10% w/w of polymer. The particles displayed good pH dependent stability in the pH range 1.1-7.4. DSC and XRD studies revealed the amorphous nature of doxorubicin in nanoparticles and the accelerated stability studies revealed the integrity of formulations. Initial biphasic release (20%) followed by a sustained release (80%) for 24 days was observed under in vitro conditions. The doxorubicin loaded nanoparticles demonstrated superior performance in vivo as evident by enhanced bioavailability and lower toxicity. Together, the data indicates the potential of doxorubicin loaded nanoparticles for oral chemotherapy. Further, these formulations could be explored for new indications like leishmaniasis.

KW - bioavailability

KW - cardiotoxicity

KW - oral delivery

KW - oxidative stress

UR - http://dx.doi.org/10.1007/s11095-008-9763-4

U2 - 10.1007/s11095-008-9763-4

DO - 10.1007/s11095-008-9763-4

M3 - Article

VL - 26

SP - 492

EP - 501

JO - Pharmaceutical Research

T2 - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 3

ER -